Breaking News

Prokarium Acquires Emergent’s Oral Vaccine Technology

Will develop an advanced oral delivery platform

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Prokarium Ltd. has acquired Emergent BioSolutions’ live Salmonella-based typhoid vaccine, Typhella, and its genetic technology spi-VEC. Prokarium will combine Typhella and spi-VEC with its genetic and formulation technologies to form Vaxonella, an oral vaccine delivery platform.   Emergent has conducted several Phase I and II trials that have shown Typhella to be safe and immunogenic as a typhoid vaccine. The combination with Prokarium’s plasmid stabilization technology, ORT-VAC, will enable the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters